Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

Abstract Background Improved outcome in tobacco smoking patients with non‐small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first‐line immunotherapy in patients with high PD‐L1 expression. In this study we...

Full description

Bibliographic Details
Main Authors: Alessio Cortellini, Andrea De Giglio, Katia Cannita, Diego L. Cortinovis, Robin Cornelissen, Cinzia Baldessari, Raffaele Giusti, Ettore D'Argento, Francesco Grossi, Matteo Santoni, Annamaria Catino, Rossana Berardi, Vincenzo Sforza, Giovanni Rossi, Lorenzo Antonuzzo, Vincenzo Di Noia, Diego Signorelli, Alain Gelibter, Mario Alberto Occhipinti, Alessandro Follador, Francesca Rastelli, Rita Chiari, Luigi Della Gravara, Alessandro Inno, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Michele Montrone, Fabrizio Citarella, Maria Vittoria Pensieri, Marco Russano, Luca Cantini, Olga Nigro, Alessandro Leonetti, Paola Bordi, Gabriele Minuti, Lorenza Landi, Alessandro De Toma, Clelia Donisi, Serena Ricciardi, Maria Rita Migliorino, Valerio Maria Napoli, Gianmarco Leone, Giulio Metro, Giuseppe L. Banna, Alex Friedlaender, Alfredo Addeo, Corrado Ficorella, Giampiero Porzio
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Thoracic Cancer
Subjects:
immunotherapy
non‐small cell lung cancer
pembrolizumab
smoking
tobacco
Online Access:https://doi.org/10.1111/1759-7714.13852

Internet

https://doi.org/10.1111/1759-7714.13852

Similar Items